Valerio Therapeutics Stock price

Equities

ALVIO

FR0010095596

Pharmaceuticals

Real-time Euronext Paris 08:21:48 2024-02-26 am EST 5-day change 1st Jan Change
0.1185 EUR -2.47% Intraday chart for Valerio Therapeutics -5.58% -28.18%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2021 4.06M 4.4M Sales 2022 1.44M 1.56M Capitalization 15.64M 16.94M
Net income 2021 -5M -5.42M Net income 2022 -19M -20.59M EV / Sales 2021 7.53 x
Net cash position 2021 7.95M 8.62M Net cash position 2022 4.45M 4.82M EV / Sales 2022 7.75 x
P/E ratio 2021
-6 x
P/E ratio 2022
-0.76 x
Employees 39
Yield 2021 *
-
Yield 2022
-
Free-Float 73.93%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.23%
1 week-4.38%
Current month-5.88%
1 month-4.76%
3 months-31.43%
6 months-46.19%
Current year-27.27%
More quotes
1 week
0.12
Extreme 0.115
0.14
1 month
0.11
Extreme 0.108
0.14
Current year
0.11
Extreme 0.108
0.17
1 year
0.11
Extreme 0.108
0.39
3 years
0.11
Extreme 0.108
0.80
5 years
0.11
Extreme 0.108
0.98
10 years
0.11
Extreme 0.108
10.45
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 21-05-31
Chief Tech/Sci/R&D Officer - -
Director/Board Member - 20-09-16
Members of the board TitleAgeSince
Director/Board Member 64 21-10-13
Director/Board Member 59 -
Director/Board Member 60 11-06-28
More insiders
Date Price Change Volume
24-02-26 0.1185 -2.47% 164 668
24-02-23 0.1215 +4.74% 63,137
24-02-22 0.116 -3.33% 76,995
24-02-21 0.12 -4.00% 119,256
24-02-20 0.125 -0.40% 168,697

Real-time Euronext Paris, February 26, 2024 at 04:16 am EST

More quotes
Valerio Therapeutics (formerly Onxeo) is a clinical-stage biotechnology company developing novel cancer drugs by targeting tumor DNA functions through unparalleled mechanisms of action in the highly sought-after field of DNA damage response (DDR). The company focuses on the development of innovative first-in-class or disruptive compounds (in-house, acquired or licensed) from translational research to human clinical proof of concept. Valerio Therapeutics has platON®, its proprietary decoy oligonucleotide chemistry platform. It is dedicated to the generation of innovative new compounds to enrich the company's product portfolio. AsiDNA® is the first compound derived from platON®, a first-in-class inhibitor developed by the company. Based on a novel decoy and agonist mechanism acting upstream of multiple DDR pathways, it is highly differentiated from the tumor DNA damage response. Valerio Therapeutics is also developing OX425, a novel platON®-generated drug candidate optimized to be a next-generation PARP inhibitor, acting on both the DNA damage response and the activation of the immune response, without inducing resistance. OX425 is currently undergoing Investigational New Drug (IND)-enabling preclinical development.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1215 EUR
Average target price
1.2 EUR
Spread / Average Target
+887.65%
Consensus

Annual profits - Rate of surprise

1st Jan change Capi.
-27.27% 20 M $
+32.01% 693 B $
+20.91% 550 B $
+3.25% 390 B $
+18.74% 328 B $
+14.92% 315 B $
+7.95% 213 B $
-5.09% 212 B $
-2.83% 201 B $
-3.58% 157 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Valerio Therapeutics - Euronext Paris
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW